Inhibition of survivin expression and mechanisms of reversing drug-resistance of human lung adenocarcinoma cells by siRNA

Chinese Medical Journal

Volumn 123, Issue 20, 2010, Pages 2901-2907

  Liu, Jing Lei ^a   Wang, Yan ^a   Jiang, Ji ^a   Kong, Rui ^a   Yang, Yan Mei ^a   Ji, Hong Fei ^a   Shi, Yu Zhi ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Chemosensitivity; Human lung adenocarcinoma; siRNA; Survivin

Indexed keywords

BETA ACTIN; CASPASE 3; CISPLATIN; CYCLIN D1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LUNG RESISTANCE PROTEIN; MESSENGER RNA; PROTEIN BCL 2; SMALL INTERFERING RNA; SURVIVIN; BIRC5 PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; RIBONUCLEOPROTEIN;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IC 50; LUNG ADENOCARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH; TUMOR VOLUME; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; DRUG RESISTANCE; GENETICS; LUNG TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CISPLATIN; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; MICROTUBULE-ASSOCIATED PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; RNA, SMALL INTERFERING; VAULT RIBONUCLEOPROTEIN PARTICLES;

EID: 79952276730     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.20.028     Document Type: Article

References (34)

1. Tanabe H, Yagihashi A, Tsuji N, Shijubo Y, Abe S, Watanabe N. Expression of survivin mRNA and livin mRNA in non-small-cell lung cancer. Lung Cancer 2004; 46: 299-304.
2. Tamm I, Wang Y, Sausville E, Scudiero D, Vigna N, Oltersdorf T, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas(CD95), Bax, caspase and anticancer drugs. Cancer Res 1998; 58: 5315-5320.
3. Lin LJ, Zheng CQ, Jin Y, Ma Y, Jiang WG, Ma T, et al. Expression of survivin protein in human colorectal carcinogenesis. World J Gastroenterol 2003; 9: 974-977.
4. Gazzaniga P, Gradilone A, Giuliani L, Gandini O, Silvestri I, Nofroni I, et al. Expression and prognostic significance of livin, survivin and other apoptosis-related genes in the progression of superficial bladder cancer. Ann Oncol 2003; 14: 85-90.
5. Tomizawa M, Saisho H, Tagawa M. Regulatory regions of growth-related genes can activate an exogenous gene of the alpha-fetoprotein promoter to a comparable degree in human hepatocellular carcinoma cells. Anticancer Res 2003; 23: 3273-3277.
6. Schultz IJ, Kiemeney LA, Witjes JA, Schalken JA, Willems JL, Swinkels DW, et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 2003; 23: 3327-3331.
7. Altieri DC. Survivin versatile modulation of cell division and apoptosis in cancer. Oncogene 2003; 22: 8581-8589.
8. Altieri DC. Survivin and apoptosis control. Adv Cancer Res 2003; 88: 31-52.
9. Zhu XD, Lin GJ, Qian LP, Chen ZQ. Expression of survivin in human gastric carcinoma and gastric carcinoma model of rats. World J Gastroenterol 2003; 9: 1435-1438.
10. Altieri DC. Survivin in apoptosis control and cell cycle regulation in cancer. Prog Cell Cycle Res 2003; 5: 447-452.
11. Wang ZH, Xie YH, Wang HB. Changes in survivin messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther 2005; 4: 716-719.
12. Ikeguchi M, Liu J, Kaibara N. Expression of survivin mRNA and protein in gastric cancer cell line (MKN-45) during cisplatin treatment. Apoptosis 2002; 7: 23-29.
13. Shinohara ET, Gonzalez A, Massion PP, Chen H, Li M, Freyer AS, et al. Nuclear survivin predicts recurrence and poor survival in patients with resected non-small cell lung carcinoma. Cancer 2005; 103: 1685-1692.
14. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134.
15. Izquierdo MA, Scheffer GL, Flens MJ, Shoemaker RH, Rome LH, Scheper RJ. Relationship of LRP-human major vault protein to in vitro and clinical resistance to anticancer drugs. Cytotechnology 1996; 19: 191-197.
16. Downword J. RNA interference. BMJ 2004; 328:1245-1248.
17. Mittal V. Improving the efficiency of RNA interference in mammals. Nat Rev Genet 2004; 5: 355-365.
18. Hannon GJ, Rossi JJ. Unlocking the potential of the human genome with RNA interference. Nature 2004; 431: 371-378.
19. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004; 351: 1772-1777.
20. Westphal S, Kalthoff H. Apoptosis: targets in pancreatic cancer. Mol Cancer 2003; 2: 6.
21. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 2006; 5: 1087-1098.
22. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-921.
23. Pennati M, Binda M, De Cesare M, Pratesi G, Folini M, Citti L, et al. Ribozyme mediated down-regulation of survivin expression sensitizes human melanoma cells to topotecan in vitro and in vivo. Carcinogenesis 2004; 25: 1129-1136.
24. Lu B, Mu Y, Cao C, Zeng F, Schneider S, Tan J, et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res 2004; 64: 2840-2845.
25. Tu SP, Jiang XH, Lin MC, Cui JT, Yang Y, Lum CT, et al. Suppression of survivin expression inhibits in vivo tumorigenicity and angiogenesis in gastric cancer. Cancer Res 2003; 63: 7724-7732.
26. Coma S, Noe V, Lavarino C, Adan J, Rivas M, Lopez-Matas M, et al. Use of siRNAs and antisense oligonucleotides against survivin RNA to inhibit steps leading to tumor angigogenesis. Oligonucleotides 2004; 14: 100-113.
27. Pennati M, Binda M, Colella G, Zoppe M, Folini M, Vignati S, et al. Ribozyme-mediated inhibition of survivin expression increases spontaneous and drug-induced apoptosis and decreased the tumorigenic potential of human prostate cancer cells. Oncogene 2004; 23: 386-394.
28. Yang JH, Zhang YC, Qian HQ. Survivin antisense oligodeoxynucleotide inhibits growth of gastric cancer cells. World J Gastroenterol 2004: 10: 1121-1124.
29. Pietenpol JA, Stewart ZA. Cell cycle checkpoint signaling: Cell cycle arrest versus apoptosis. Toxicology 2002; 27: 475-481.
30. Li F, Ambrosini G, Chu EY, Plescia J, Tognin S, Marchisio PC, et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-584.
31. Henkels KM, Turchi JJ. Cisplatin-induced apoptosis proceeds by caspase-3-dependent and independent pathways in cisplatin-resistant and sensitive human ovarian cancer cell lines. Cancer Res 1999: 59: 3077-3083.
32. Volm M, Koomagi R, Mattern J. Interrelationships between microvessel density, expression of VEGF and resistance to doxorubicin of non-small lung cell carcinoma. Anticancer Res 1996; 16: 213-217.
33. Xiao B, Shi YQ, Zhao YQ, You H, Wang ZY, Liu XL, et al. Transduction of Fas gene or Bcl-2 antisense RNA sensitizes cultured drug resistance gastric cancer cells to chemotherapeutic drugs. World J Gastroenterol 1998; 4: 421-425.
34. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-134.